Aggressive, refractory multiple sclerosis warrants unconventional therapy. A retrospective multicentre study assessed the effects of ablating the immune system, then reconstituting it using bone marrow derived stem cells. Though this particular regimen improved disability in some patients, others continued to relapse, perhaps indicating the treatment did not go far enough.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pfender, N., Saccardi, R. & Martin, R. Autologous hematopoietic stem cell transplantation as a treatment option for aggressive multiple sclerosis. Curr. Treat. Options Neurol. 15, 270–280 (2013).
Burman, J. et al. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. J. Neurol. Neurosurg. Psychiatry http://dx.doi.org/10.1136/jnnp-2013-307207.
Edan, G. et al. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. J. Neurol. Neurosurg. Psychiatry 12, 1344–1350 (2011).
Weiner, H. L. Immunosuppressive treatment in multiple sclerosis. J. Neurol. Sci. 223, 1–11 (2004).
Coles, A. J. et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380, 1829–1839 (2012).
Freedman, M. S. 'Time is brain' also in multiple sclerosis. Mult. Scler. 15, 1133–1134 (2009).
Scalfari, A. et al. The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability. Brain 133, 1914–1929 (2010).
Freedman, M. S. et al. Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can. J. Neurol. Sci. 40, 307–323 (2013).
Menon, S. et al. Characterising aggressive multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 84, 1192–1198 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Freedman, M. Does aggressive MS warrant aggressive treatment?. Nat Rev Neurol 10, 368–370 (2014). https://doi.org/10.1038/nrneurol.2014.98
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2014.98